Feature Article

Personalized Medicine in Psoriasis: Patient Stratification Is Key Step Forward


Although truly personalized medicine is not yet feasible in psoriasis treatment, a stratified approach to selection of therapies may offer some of the benefits of personalized medicine.

The relative risk for healthcare-associated infections has decreased in the last 15 years due to improvements in awareness of risk associated with devices, infection control, and evidence-based practice regarding use of devices.

Latest News


Physician's Global Assessment Reliable for Evaluating Disease Activity in Psoriatic Arthritis

By July 16, 2018

Researchers sought to assess the reliability of the PGA for musculoskeletal and dermatologic manifestations in patients with psoriatic arthritis.


Early, Sustained Improvements With Apremilast in Biologic-Naive Psoriatic Arthritis

By July 13, 2018

In biologic-naive patients with psoriatic arthritis who are treated with apremilast, early onset of effect was observed across disease PsA manifestations.


Similar Quality of Life Reported in Rheumatoid Arthritis, Psoriatic Arthritis

By July 13, 2018

Health-related quality of life was similar in patients with rheumatoid arthritis and psoriatic arthritis.


More Research Needed on S aureus Colonization in Psoriasis

By July 05, 2018

Controlled studies to evaluate the benefits of a universal or targeted decolonization program in patients with psoriasis is warranted.


Ixekizumab Effective for Long-Term Treatment of Plaque Psoriasis

By July 04, 2018

Similar response rates were observed in patients with baseline scalp, nail, or palmoplantar involvement.


Antibiotic-Methotrexate Combo Leads to Serious Side Effects in RA Patient

By June 28, 2018

The case involved a 68-year-old female patient with rheumatoid arthritis on methotrexate 10mg weekly who presented to the emergency department with complaints of lethargy and weakness after being prescribed a 2-week course of TS for a bacterial skin infection.


Psoriasis Treatment With Biologics Often Requires Multiple Courses, Treatment Changes

By June 26, 2018

The final analysis set comprised biologic-naïve individuals — individuals who had filled an initial prescription for etanercept, infliximab, adalimumab, or ustekinumab after 2 years without using any biologic agent during the study period.


Glucocorticoid Cumulative Dose Has No Effect on BMD, Fracture Risk in Psoriasis, PsA

By June 18, 2018

The objective of this cross-sectional analysis was to evaluate the prevalence of osteoporosis and frequency of fractures in patients with psoriasis or psoriatic arthritis.


Many Psoriasis Patients Have Not Achieved Clear Skin, Despite Its Possibility

By June 15, 2018

Participants who did not have clear/almost clear skin reported that achieving clear/almost clear skin would open new possibilities, such as swimming, trying on new clothes, and meeting new people.


Adalimumab Associated With Reduced Inflammation in Psoriasis

By June 15, 2018

Larger studies with more detailed phenotyping of vascular disease are warranted to evaluate the comparative differences in the effects of adalimumab and phototherapy that were observed in the current study.

Sign up for Newsletters